IMR Press / FBL / Volume 10 / Issue 2 / DOI: 10.2741/1683

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Uncoupling protein-2 and non-alcoholic fatty liver disease
Show Less
1 Liver Research Center, Division of Gastroenterology, Rhode Island Hospital, Brown Medical School, Providence, RI 02903, USA

Academic Editor: Nobuhiro Sato

Front. Biosci. (Landmark Ed) 2005, 10(2), 2082–2096;
Published: 1 September 2005
(This article belongs to the Special Issue Non alcoholic fatty liver disease NAFLD)

Non-alcoholic fatty liver disease (NAFLD) has become the most common form of hepatic disorders in the developed world. NAFLD is part of the metabolic syndrome with insulin resistance as a primary underlying derangement. The natural history of NAFLD may extend from simple steatosis over steatohepatitis into cirrhosis and hepatocellular carcinoma. Among numerous factors shaping these transitions, uncoupling protein-2 (UCP2) may theoretically contribute to every stage of this disease. UCP2 is a recently identified fatty acid-responsive mitochondrial inner membrane carrier protein showing wide tissue distribution with a substantially increased presence in fatty liver. The biological functions of UCP2 are not fully elucidated and the greater part of our current knowledge has been obtained from animal experiments. These data suggest a role for UCP2 in lipid metabolism, mitochondrial bioenergetics, oxidative stress, apoptosis, and even carcinogenesis. Available evidence is reviewed and new concepts are considered to appraise the potential role of UCP2 in the pathogenesis of NAFLD.

Uncoupling Protein-2
Electron Transport Chain
Oxidative Phosphorylation
Proton Leak
Mitochondrial Membrane Potential
Reactive Oxygen Species
Fatty Acids
AMP-Activated Kinase
NonAlcoholic Fatty Liver Disease
Non-Alcoholic Steatohepatitis
Cryptogenic Cirrhosis
Hepatocellular Cancer
Back to top